CTIS2023-505733-28-00进行中（未招募）1 期
Chronic anticoagulation in end-stage renal disease patients: pharmacocinetics and pharmacodynamic of a reduced dose regimen of rivaroxaban (CARD-AXA)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Adult patient = 18 years, Chronic haemodialysis for at least 3 months, Participants covered by or entitled to social security, Patients who have signed a written informed consent form
排除标准
- •Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, persons subject to a legal protection measure: guardianship or trusteeship), Severe hepatic insufficiency, Use of powerful CYP3A4 inducers (in particular rifampicin, phenytoin, carbamazepine, phenobarbital or St John's wort (Hypericum perforatum)), Use of treatments that inhibit CYP3A4 and gp-P, in particular azole antifungals (ketoconazole, itraconazole, voriconazole, posaconazole, fluconazole, HIV protease inhibitors, clarithromycin and erythromycin)., Contraindication to anticoagulant treatment, such as anti-phospholipid antibody syndrome, Contraindications to the administration of rivaroxaban, Patient registered on the renal transplant list and refusing temporary contraindication for the duration of the study, Patients for whom the investigator considers that they will be unable to undergo the protocol treatment, for whatever reason, Patient already taking part in an ongoing study or having taken part in a study which ended less than 30 days before the inclusion date, Women of childbearing age not using a highly effective method of contraception for the duration of the study., Any indication for long-term oral anticoagulation (atrial fibrillation, thromboembolic venous disease, mechanical valve prosthesis, intracardiac thrombosis, etc), Double anti-platelet aggregation for any reason or a dose of aspirin greater than 160 mg per day, Uncontrolled arterial hypertension (BP > 180/110 mmHg), Ischaemic stroke in the 30 days prior to inclusion, History of major unprovoked haemorrhage (leading to hospitalisation or transfusion), regardless of how long it has existed, Surgery in the 30 days prior to inclusion, High-risk bleeding pathology in addition to renal failure, such as a known coagulation disorder, thrombocytopenia (< 100G/L), progressive neoplasia of the digestive or urinary tract, or the presence of an intracranial vascular malformation
研究者
相似试验
已完成
不适用
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS DataVenous Thromboembolic DiseaseKidney Failure, ChronicNCT04818151Johns Hopkins University14,914
招募中
3 期
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease PatientsChronic Hemodialysis PatientsNCT05410275University Hospital, Tours10
已完成
不适用
Hemolysis of patients with end stage renal disease evaluated by erythrocyte creatineEnd stage renal diseaseJPRN-UMIN000036418Kansai Medical University Medical Center69
尚未招募
不适用
Blood clotting disorders in kidney diseaseCTRI/2020/10/028389POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH CHANDIGARH
已完成
不适用
Prevalence of Antiphospholipid Antibodies in the Hemodialysis Patients Population Within the CHU Brugmann HospitalAntiphospholipid SyndromeNCT03893357Brugmann University Hospital100